ClinicalTrials.gov, the registry where any legitimate trial must appear before enrollment, returns zero studies for the compound, and no trial report exists in the PubMed literature
Actin Sequestration and Cytoskeletal Remodeling TB-500 functions as the primary actin-sequestering molecule in the blend, binding globular actin (G-actin) and regulating actin polymerization[2]
(The 503A Bulks List is a list of drug substances that the FDA has approved for compounding.) The committee recommended six of those peptidesBPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semaxbe moved onto the list so that they can be legally prescribed and compounded in the future
In some cases, this happens spontaneously, but more often it happens as a result of supportive dietary and lifestyle changes, nutritional therapies, medication, or surgery
, DSIP 60